Multi-modal treatment with peptide vaccine, metronomic cyclophosphamide and anti-PD1 monoclonal antibody provides effective control of tumors in multiple models

Meeting abstracts Future cancer immunotherapies will combine multiple treatments to improve immune responses to cancer through synergistic, multi-modal mechanisms. In a Phase I clinical trial, we found that the immune response to a peptide vaccine targeting survivin, DPX-Survivac, by ovarian cancer